Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
typical algo pop & drop 1.07-1.43-1.12
$BNOX NEWS
https://finviz.com/quote.ashx?t=BNOX&ty=c&ta=1&p=d
https://dilutiontracker.com/app/search/BNOX?a=dbb88c
Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder $BNOX https://t.co/hjkdSlL4I5
— Health Stocks News (@health_stocks) March 21, 2024
It looks like it had a 7x day(s) in October
Good luck .
Hope all is better. I did not see this post till Feb 29th
Still adding to my $BNOX stash
this will have a 10x day soon imo
BNOX
Great; been busy with a great grandchildren; Seline along with Santino, her bother, where born 26 weeks early. He is home now while Seline is still hospitalized with Short Bowel Syndrome; she has had 6 surgeries, lost all but 7 inches of her small intestine. Waiting for transfer to an Omaha, Nebraska, hospital.
Stock doing well, I hope it goes to a dollar soon so I will be able to offer greater support. I have 170K shares.
HammerTime im getting a richme too
HammerTime !!!
Congrats !!!!
Holy Shilt Batman !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
HAMMERTIME !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
No. As a player, I am certainly well versed in that score.
volume disappeared, but pps holding. who knows.
I thought it might retest the highs. From up 15% to down 5%.
i think it already did
BNOX.....Been accumulating low 4's. since Friday....waiting for a pop
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172988579 October 19 run coming?
Billionaires are buying this stock.
That is all you need to know.
Seems like a number of "investors or sharks" gravitate to a core of shares then the shares tank as they depart. There is no mystery to it.
BNOX: Yep, those articles got me monster CONFUSED about what was REALLY going on. But we all know that when a Company's 'Insiders' --- or even 'Outsiders' --- BUY big slices of that Firm's shares, such is normally GREAT news. But anathema to any Firm is when those 'Insiders' DUMP same. Bottom line though, BNOX is a MYSTERIOUS play.
I see it was milked well the last few days. Where there were many many AM posts on in September, not a one today. Guess you will wait until in drops below $3 then start building it up a hundred shares at a time until enough suckers jump in then and only then start selling.
Isn't stock manipulation a crime?
Hey dude thank you so much for the links. Yea we all thought the float was nothing. Remember I posted here like 5 weeks ago that this was delisted from the Australian stock exchange? It was the Companies doing. That exchange is way too conservative and I feel they would have put the brakes on trading.
Seems like to me; I did not buy any but did notice the large run up and about a 2/3 drop afterwards. True it recovered part of the distance into the low $4's.
Of course PIXY was supposed to be on the up and up until flippers flipped the daylights out of it. There a lost a good chunk of change.
CNTX is now also receiving honorable mention but absent flippers nothing will happen. I won't buy anything of that either. I am trying to learn the ways of the money makers. How is it; buy early with stocks are most volatile, then throw a morsel or two to late comers. Sure you notice there are many trades 10 and 100, maybe a little higher probably flippers that loaded up early?
Thanks for the post. I started a list of main players across all the recent "great stocks." , for example PIXY, BNOX, now CNTX, by the key players. Maybe I will learn which stocks to avoid.
I think this link reveals how things work. You tell me if you find BNOX flipper driven? Seems it's been pretty hot and for multiple days. Something must be behind that on these otherwise down market days.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172952944
Flipper driven??
The next BNOX?
Whether It’s Cloudy Or Sunny, You Should Be Buying Context Therapeutics (CNTX)
(Take a look at CONTEXT Therapeutics) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting could alert investors to a potential blockbuster. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing their results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the potential market value of a pending CLND6 blockbuster. There are also other irons in the fire at Context Therapeutics to maintain share holder excitement as well. Stay tuned for updates on the pipeline as fact checking is near completion. CNTX stock has been beaten down just like the shares of Viking Therapeutics (VKTX) had been before running up to over $25 a share.
Right now the shares of CNTX are held tight and likely have only a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock as a buy. There is a growing consensus among some investors that forecast is far to conservative with a $6-$15 range seeming a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this. Don't believe it? Look over Viking Therapeutics (VKTX) where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
Pull back after $5.15 hod
Sure is. Couple of nice days returning back up.
Looking strong!
BNOX: Curious article from today here, but the SIZE of the SHARES stake in BNOX seems to be a gross misprint --- when compared to the "OTCMarkets" website's rendering of the "Shares Structure" for the BNOX Firm..
https://beststocks.com/point72-asset-management-lp-reveals-significa/
https://www.otcmarkets.com/stock/BNOX/security
(Take a look at CNTX) CLDN6 is in development by Context Therapeutics (CNTX) and is designed to be activated only upon tumor engagement while silent elsewhere. This allows CLDN6 to redirect T-cell activation away from where it would be harmful and enhances the safety profile vs its peers and what they are developing. There is an immense market given the absolute need for a high specificity to solid tumor cell treatment. $6-$15 a share is reasonable within 12 months given the upcoming Society for Immunotherapy of Cancer meeting will alert investors to the potential. CNTX shares could easily climb multiples times higher given the tightly held float. By the time investors realize claudin 6 is an exceptionally attractive investment CNTX shares will likely be trading over $4 a share and heading higher. At the point clinical trails start showing results be prepared to pony up for shares. There is opportunity to get in before the bulk of investors learn the market value of a pending CLND6 blockbuster. There are other irons in the fire at Context Therapeutics fir share share holder excitement as well. Stay tuned for udates on the pipeline as fact checking is near completion. CNTX stock had been beaten down just like the shares of Viking Thereputics(VKTX) Had been before running up to over $25 a share.
Right now the shares CNTX shares are held tight and only have a small pool available. The 12-month stock price forecast for CNTX stock is $4.00, which predicts an increase of 164.90%. On average, analysts rate CNTX stock stock as a buy. There is a growing consensus that forecast is far to conservative. $6-$15 seems a more realistic target within a year. Do some homework and see the opportunity before the masses. Things tend to get heated early with real potential like this.... Don't believe it? Look over VKTX where it traded under $2 a share. CNTX isn't different it's poised for the same type of breakout. Look at the 5 year chart and your eye will be open.
$4.00 :)
Tiny float
Up nice this morning
This is far from over IMO. And not everything is riding on that one drug. If you haven't already, look back through other recent PR & filings.
https://www.nasdaq.com/market-activity/stocks/bnox/press-releases
Look at the way BNOX is trading. Looking at CNTX instead looks like BNOX before the run up. Lower shares than BNOX and ground floor anything under $4 so we are talking really good returns on the upcoming events.
BNOX Recap
I was out looking for a larger whse space yesterday. So, let's examine yesterday's Runner BNOX now to see what we can learn.
Bionomics Limited is a clinical stage biopharmaceutical company. It was up a whopping 570% at one point yesterday, hitting two of our five positive scans we follow each morning: Most Actives #1 and Highest % Gainers #1. It closed regular session up 240%.
The paramount question with Runners is, "is it somewhat warranted (somewhat bc 570% is rarely warranted) or is a POS stock the "boys" got hold of, as stuffy was wont to say.
The News: Why Is Stress Disorder Focused Bionomics Stock Trading Higher Today?
BENZINGA 8:24 AM ET Sep-28-2023
Bionomics Limited (NASDAQ:BNOX) announced topline results from its Phase 2b ATTUNE trial of BNC210 for post-traumatic stress disorder (PTSD).
The trial met its primary endpoint of change in the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total symptom severity score from baseline to Week 12 (p=0.048).
A statistically significant change in CAPS-5 score was also observed at Week 4 (p=0.015) and at Week 8 (p=0.014).
Treatment with BNC210 also showed statistically significant improvement in clinician-administered and patient self-reporting in two of the trial's secondary endpoints.
Specifically, BNC210 led to significant improvements at Week 12 in depressive symptoms (p=0.040) and sleep (p=0.041) as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) and Insomnia Severity Index (ISI), respectively.
BNC210 also showed signals and trends across visits in the other secondary endpoints, including the clinician and patient global impression-symptom severity (CGI-S, PGI-S) and the Sheehan Disability Scale (SDS).
Treatment with 900 mg twice daily BNC210 had a favorable safety and tolerability profile.
Additionally, the Company recently held a Phase 3-enabling End-of-Phase 2 meeting with the FDA to advance BNC210 for the acute treatment of social anxiety disorder into registrational studies and is awaiting receipt of the formal meeting minutes.
Price Action: BNOX shares are up 387.30% at $4.80 during the premarket session on the last check Thursday.
That's significant news. Phase one is just to prove taking the candidate doesn't make you spin around three times and fall to the floor like a wood plank. Phase Two proves efficacy or not and Bionomics reported it met all endpoints, So, the pop was warranted.
Present trading: BIONOMICS LTD $2.9498 -0.4202 (-12.47%)
As of Sep-29-202311:01:17 AM ET
Volume 4,435,157
10/90-day avg. vol. - 13M / 2M
https://stockcharts.com/h-sc/ui?s=BNOX
Day range $2.83 - $3.56
52-week range $0.9300 - $10.90
MG for $Stock*Shop*Charts*News*Option$ board
BNOX: Trying to breakout
Followers
|
5
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
187
|
Created
|
03/07/23
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |